Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker PCSA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 3,057 | $1.93 | $5,900 Buy | Form 4 ↗ |
| Jun 30, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,436 | $1.93 | $4,701 Buy | Form 4 ↗ |
| Jun 30, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,106 | $1.93 | $4,065 Buy | Form 4 ↗ |
| Jun 30, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 3,277 | $1.93 | $6,325 Buy | Form 4 ↗ |
| Jun 30, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,531 | $1.93 | $4,885 Buy | Form 4 ↗ |
| Jun 15, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,067 | $2.22 | $4,589 Buy | Form 4 ↗ |
| Jun 15, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,654 | $2.22 | $5,892 Buy | Form 4 ↗ |
| Jun 15, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,465 | $2.22 | $5,472 Buy | Form 4 ↗ |
| Jun 15, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,831 | $2.22 | $4,065 Buy | Form 4 ↗ |
| Jun 15, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,118 | $2.22 | $4,702 Buy | Form 4 ↗ |
| May 29, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,786 | $2.57 | $4,590 Buy | Form 4 ↗ |
| May 29, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,292 | $2.57 | $5,890 Buy | Form 4 ↗ |
| May 29, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,129 | $2.57 | $5,472 Buy | Form 4 ↗ |
| May 29, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,582 | $2.57 | $4,066 Buy | Form 4 ↗ |
| May 29, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,829 | $2.57 | $4,701 Buy | Form 4 ↗ |
| May 15, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,843 | $2.97 | $5,474 Buy | Form 4 ↗ |
| May 15, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,545 | $2.97 | $4,589 Buy | Form 4 ↗ |
| May 15, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,369 | $2.97 | $4,066 Buy | Form 4 ↗ |
| May 15, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,583 | $2.97 | $4,702 Buy | Form 4 ↗ |
| May 15, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,984 | $2.97 | $5,892 Buy | Form 4 ↗ |
| Apr 30, 2026 | Sian Bigora Chief Development Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,971 | $2.71 | $5,341 Buy | Form 4/A ↗ |
| Apr 30, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,706 | $2.69 | $4,589 Buy | Form 4 ↗ |
| Apr 30, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,190 | $2.69 | $5,891 Buy | Form 4 ↗ |
| Apr 30, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,034 | $2.69 | $5,471 Buy | Form 4 ↗ |
| Apr 30, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,511 | $2.69 | $4,065 Buy | Form 4 ↗ |
| Apr 30, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,748 | $2.69 | $4,702 Buy | Form 4 ↗ |
| Apr 15, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,843 | $2.97 | $5,474 Buy | Form 4/A ↗ |
| Apr 15, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,843 | $2.97 | $5,474 Buy | Form 4/A ↗ |
| Apr 15, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,545 | $2.97 | $4,589 Buy | Form 4 ↗ |
| Apr 15, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,369 | $2.97 | $4,066 Buy | Form 4 ↗ |
| Apr 15, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,583 | $2.97 | $4,702 Buy | Form 4 ↗ |
| Apr 15, 2026 | Sian Bigora Chief Development Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,799 | $2.97 | $5,343 Buy | Form 4 ↗ |
| Apr 15, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,984 | $2.97 | $5,892 Buy | Form 4 ↗ |
| Mar 31, 2026 | George K. Ng Chief Executive Officer, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,136 | $2.54 | $5,425 Buy | Form 4/A ↗ |
| Mar 31, 2026 | James R. Neal Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 789 | $2.54 | $2,004 Buy | Form 4 ↗ |
| Mar 31, 2026 | David Young Pres. Research & Development, Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,810 | $2.54 | $4,597 Buy | Form 4 ↗ |
| Mar 31, 2026 | Russell Skibsted Chief Financial Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,324 | $2.54 | $5,903 Buy | Form 4 ↗ |
| Mar 31, 2026 | Geraldine Pannu Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,072 | $2.54 | $5,263 Buy | Form 4 ↗ |
| Mar 31, 2026 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,603 | $2.54 | $4,072 Buy | Form 4 ↗ |
| Mar 31, 2026 | Wendy Guy Chief Administrative Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 1,854 | $2.54 | $4,709 Buy | Form 4 ↗ |
| Mar 31, 2026 | Sian Bigora Chief Development Officer | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,107 | $2.54 | $5,352 Buy | Form 4 ↗ |
| Mar 31, 2026 | Khoso Baluch Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 2,269 | $2.54 | $5,763 Buy | Form 4 ↗ |
| Jan 27, 2025 | Justin W. Yorke Director | PCSA Processa Pharmaceuticals, Inc. | Buy | 12,400 | $0.80 | $9,920 Buy | Form 4 ↗ |
| Jan 27, 2025 | Patrick Lin Chief Business - Strategy Off | PCSA Processa Pharmaceuticals, Inc. | Buy | 43,500 | $0.80 | $34.8K Buy | Form 4 ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:13 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances